UPSTREAM BIO INC (UPB) Stock Price, Quote, News and Overview
NASDAQ:UPB - Nasdaq - US91678A1079 - Currency: USD
UPB Quote, Performance and Key Statistics
UPSTREAM BIO INC
NASDAQ:UPB (1/24/2025, 8:12:55 PM)
After market: 10.39 0 (0%)10.39
-0.38 (-3.53%)
The current stock price of UPB is 10.39 USD. In the past month the price decreased by -42.05%.
UPB Latest News, Press Releases and Analysis
Upstream Bio Enters Oversold Territory (UPB)
Upstream Bio Announces Addition to Russell 2000® Index
Upstream Bio (Nasdaq:UPB) to be added to Russell 2000® index effective at the open of the U.S. equities market on Monday, December 23....
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise.
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market.
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Upstream closes $293 million upsized IPO including full exercise of underwriters’ option to purchase additional shares...
UPB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.84 | 300.94B | ||
| AMGN | AMGEN INC | 14.33 | 148.05B | ||
| GILD | GILEAD SCIENCES INC | 21.01 | 115.99B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 862 | 113.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.88 | 74.26B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.80B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.47B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.64B | ||
| NTRA | NATERA INC | N/A | 22.13B | ||
| BIIB | BIOGEN INC | 8.95 | 21.30B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.52B |
Related stock screener links
About UPB
Company Profile
Upstream Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Waltham, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2024-10-11. Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The firm is developing verekitug, the only known antagonist in development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin. The firm has advanced this highly potent monoclonal antibody into separate Phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and plans to initiate development of chronic obstructive pulmonary disease (COPD).
Company Info
UPSTREAM BIO INC
890 Winter Street, Suite 200
Waltham MASSACHUSETTS US
Employees: 35
Company Website: https://upstreambio.com/
Phone: 17812082466
UPB FAQ
What is the stock price of UPB?
The current stock price of UPB is 10.39 USD.
What is the symbol for UPSTREAM BIO INC stock?
The exchange symbol of UPSTREAM BIO INC is UPB and it is listed on the Nasdaq exchange.
On which exchange is UPB stock listed?
UPB stock is listed on the Nasdaq exchange.
Is UPB a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for UPB, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of UPB.
Does UPB stock pay dividends?
UPB does not pay a dividend.
What is the Price/Earnings (PE) ratio of UPB?
UPB does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.75).
What is the Short Interest ratio of UPB stock?
The outstanding short interest for UPB is 6.13% of its float.
UPB Technical Analysis
UPB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UPB. No worries on liquidiy or solvency for UPB as it has an excellent financial health rating, but there are worries on the profitability.
UPB Financial Highlights
Over the last trailing twelve months UPB reported a non-GAAP Earnings per Share(EPS) of -0.75. The EPS decreased by -60.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.44% | ||
| ROE | -17.34% | ||
| Debt/Equity | 0 |
UPB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to UPB. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -987.79% and a revenue growth -6.51% for UPB